Enabling and optimizing perfusion for intensified production of CAR-T cells in stirred tank bioreactors

Cell & Gene Therapy Insights 2024; 10(4), 319–326

DOI: 10.18609/cgti.2024.047

Published: 15 May
Innovator Insight
Qasim Rafiq, Julia Hengst

As the CAR-T cell therapy sector battles to reduce manufacturing cost of goods and processing timeframes, Qasim Rafiq, Professor of Cell and Gene Therapy Bioprocessing at UCL, and Julia Hengst, External Collaborations Manager, Cell Culture Technologies at Sartorius, tell BioInsights about recent studies demonstrating the value of stirred tank bioreactors in accelerating CAR-T process development, intensification, optimization, and stream-lining scale-up.